- Home
- AURE vs NRXP Comparison
AURE vs NRXP Comparison
Compare AURE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AURE | NRXP |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 70.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AURE | NRXP |
|---|---|---|
| Price | $0.30 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 01-06-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,785,569.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 434.30 | N/A |
| 52 Week Low | $0.23 | $1.58 |
| 52 Week High | $2.70 | $3.84 |
Technical Indicators
Market Signals| Indicator | AURE | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 42.37 |
| Support Level | $0.24 | $2.04 |
| Resistance Level | $0.32 | $2.38 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 69.77 | 23.60 |
Price Performance
Historical ComparisonAbout AURE Prestige Wealth Inc. Class A Ordinary Shares
Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.